Objective: Biomarkers aid diagnosis, allow inexpensive screening of therapies, and guide selection of patient-specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease-modifying therapy without understanding patient-specific drivers of disability. Therefore, using multiple sclerosis (MS) as an example of a complex polygenic neurological disease, we sought to determine whether cerebrospinal fluid (CSF) biomarkers are intraindividually stable, cell type-, disease-and/or process-specific, and responsive to therapeutic intervention. Methods: We used statistical learning in a modeling cohort (n 5 225) to develop diagnostic classifiers from DNAaptamer-based measurements of 1,128 CSF proteins. An independent validation cohort (n 5 85) assessed the reliability of derived classifiers. The biological interpretation resulted from in vitro modeling of primary or stem cellderived human CNS cells and cell lines. Results: The classifier that differentiates MS from CNS diseases that mimic MS clinically, pathophysiologically, and on imaging achieved a validated area under the receiver operating characteristic curve (AUROC) of 0.98, whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a validated AUROC of 0.91. No classifiers could differentiate primary progressive from secondary progressive MS better than random guessing. Treatment-induced changes in biomarkers greatly exceeded intraindividual and technical variabilities of the assay. Interpretation: CNS biological processes reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific. This opens opportunities for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorders.
drugs that collectively target all pathological processes that underlie expression of a disease in a particular patient.
In contrast, neurologists lack tools that provide reliable information about the dysfunction of constituent cells of the central nervous system (CNS). This ambiguity leads to 20 to 40% diagnostic errors, 1,2 slow therapeutic progress, 3 and suboptimal clinical outcomes.
Complex neurological disorders such as multiple sclerosis (MS) are generally treated by a single disease-modifying treatment (DMT), without understanding patient-specific drivers of disability. The multiplicity of mechanisms in neurodegenerative diseases and heterogeneity within patient populations makes successful treatment by a single therapy unlikely. Conversely, proving clinical efficacy of a single therapy is difficult precisely because of the limited contribution of the targeted mechanism to the overall disease process. Thus, reliable quantification of diverse pathogenic processes in the CNS of living subjects is a prerequisite for broad therapeutic progress in neurology. Although cerebrospinal fluid (CSF), an outflow of CNS interstitial fluid, 4 is an ideal source for molecular biomarkers, remarkably few CSF biomarkers have reached clinical practice or drug development. 5 This reality is partly based on a circular argument; CSF examinations are not implemented in clinical trials or clinics because of a lack of validated, commercially available biomarker measurements, while reliable data on surrogacy of biomarkers to clinical outcomes can be obtained only from clinical trials or wide clinical use. Consequently, the goal of this proof-of-concept study was to investigate on the example of MS the following hypotheses: (1) a subset of CSF biomarkers are intraindividually stable in the absence of disease process or therapeutic intervention, and such biomarkers can be assembled into clinically useful tests; (2) a subgroup of CSF biomarkers have restricted cellular origin and can be used to develop clinically useful classifiers; (3) healthy and different disease states of the CNS are sufficiently dissimilar on a molecular level that CSF biomarker-based classifiers can differentiate a specific disease from those that have similar clinical phenotype, pathophysiology, or imaging features; (4) CSF biomarker-based classifiers can also quantify evolution of a single disease process, thus differentiating its stages; and (5) therapy-induced changes in CSF biomarkers can be readily distinguished from intraindividual variability, demonstrating that CSF biomarkers could serve as pharmacodynamic markers in drug development.
Subjects and Methods

Subjects
Subjects were prospectively recruited (May 2009 -March 2015 as part of a Natural History protocol "Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System" (ClinicalTrials.gov identifier: NCT00794352). The patients' eligibility criteria included age 18 to 75 years and presentation with a clinical syndrome consistent with immune-mediated CNS disorder or neuroimaging consistent with inflammatory or demyelinating CNS disease. The inclusion criteria for healthy donors (HDs) were age 18 to 75 years, with vital signs within normal range at the time of the screening visit. The diagnostic workup included a neurological examination, magnetic resonance imaging (MRI) of the brain, and laboratory tests (blood, CSF) as described. 6 Diagnoses of relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS) were based on 2010 revised McDonald diagnostic criteria. 7 The remaining subjects were classified as either other inflammatory neurological disorders (OIND; eg, meningitis/encephalitis, Susac syndrome, CNS vasculitis, systemic lupus erythematosus, and genetic immunodeficiencies with CNS inflammation) or noninflammatory neurological disorders (NIND; eg, epilepsy, vascular/ischemic disorders, leukodystrophy) based on the evidence of intrathecal inflammation as published. 6, 8 The final clinical diagnostic classification was based on longitudinal follow-up, but reached prior to development of SOMAscan-based diagnostic classifiers. The vast majority of subjects (with few OIND exceptions described elsewhere 6 ) were not treated by any DMTs at the time of CSF collection.
Clinical information on the validation cohort (n 5 85) were not available to developers of the diagnostic classifiers, and the results of the molecular diagnostic tests were not available to clinicians determining diagnoses.
CSF Collection and Processing
CSF was collected on ice and processed according to a written standard operating procedure. Research CSF aliquots were assigned prospective alphanumeric codes, and centrifuged (335 g for 10 minutes at 48C) within 15 minutes of collection. The CSF supernatant was aliquoted and stored in polypropylene tubes at 2808C until use.
SOMAscan
SOMAscan (SomaLogic, Boulder, CO) is a relative quantification of 1,128 proteins (ie, SOMAScan version available between June 2012 and October 2016 9 ) or 1,300 proteins (ie, SOMAScan version available after October 2016) using singlestranded DNA molecules synthesized from chemically modified nucleotides (SOMAmers; Slow Off-rate Modified DNA Aptamers). Chemical modifications enhance affinity binding to specific proteins. SOMAmers play a dual role of protein affinity-binding reagents and a DNA sequence recognized by complementary DNA probes. This enables quantification of individual protein concentration using a DNA concentration quantified by hybridization. [10] [11] [12] The raw data (relative fluorescent units [RFUs] ) are normalized and calibrated; hybridization normalization uses a set of 12 hybridization controls, and a common pooled calibrator corrects for plate-to-plate variation.
SOMAScan focuses on secreted soluble proteins, using a single discovery platform for all research applications. ), human microglia cell line (CHME5; provided by Nazira ElHage, Florida International University, FL), and human choroid plexus epithelial cells (hCPEpiC; ScienCell) were plated (10 5 cells/ml, 10ml/flask). Cells were treated with PBMC culture media (control) and an inflammatory mediator (supernatant from lipopolysaccharide-and CD3/CD28 beads-stimulated human PBMCs; 50% vol/vol). Oligodendrocytes were differentiated from the NIH-approved human embryonic stem cell line RUES1 using published protocol.
Assessment of Cellular
14 Cell-culture supernatants were collected after 24-hour incubation and frozen until use.
Measuring Signal-to-Noise Ratio in Biomarkers
Differences in biomarker measurements in identical samples analyzed blindly at different times (n 5 29, 88 samples) quantified the technical variability. Similarly, differences in longitudinal samples of HDs (n 5 11, 24 samples) collected 1 year apart quantified the biological variation. From each technical or biological replicate, we calculated the relative percentage change for each SOMAmer as the difference in the repeated measures divided by the average of the replicates.
To constrain the number of biomarkers used for statistical learning, we calculated signal-to-noise ratios (SNRs) using R statistical software 15 as exemplified in Figure 1A . Briefly, we estimated the residual variance for each log-transformed biomarker from a linear mixed model, 16 after accounting for subject-to-subject variation using the random intercept adjustment. The residual variance measured when identical samples were analyzed repeatedly represents "technical" variation (ie, variation caused by differences in assay runs). Analogously, the variance measured in multiple different CSF samples derived from individual HDs represents "biological" variation (ie, intraindividual variation in healthy state). A third type of variance, which we call "clinical," reflects how individual biomarkers vary in the presence of different disease states (eg, variation across all disease states). This variance was estimated by using one observation for each biomarker from each of the n 5 225 subjects in the training dataset. 
Area under the Receiver Operating Characteristics Curve
The area under the receiver operating characteristics curve (AUROC; R statistical software using the roc function in the pROC package 17 ) quantified the ability of biomarkers, biomarker ratios, and diagnostic classifiers to differentiate diagnostic categories. Higher AUROC values imply a larger potential for separating diagnostic groups. The AUROCs were calculated for the 124,750 ratios formed from the top 500 SNR SOMAmers in the modeling cohort (n 5 225), and these were used to restrict the number of biomarker ratios used for statistical learning. Graphical exploration of the distributions of the SNR and AUROCs was used to determine cutoffs for the best ratios on the 2 criteria in each situation. For differentiating MS (RRMS, PPMS, SPMS) from non-MS subjects (OIND, NIND, HD), cutoffs of AUROC > 0.65 and SNR > 0.75 were selected. Similarly, cutoffs of AUROC > 0.7 and SNR > 0.7 were used in differentiating progressive (PPMS, SPMS) MS from RRMS. Finally, cutoffs of AUROC > 0.65 and SNR > 0.65 were used for differentiating SPMS from PPMS. Ratios meeting these cutoffs were used in statistical learning to assemble diagnostic classifiers.
The performance of resulting classifiers was assessed by AUROC, along with its 95% confidence interval (CI), in the independent validation cohort.
Statistical Learning to Develop Diagnostic Classifiers Using a Random Forest Methodology
Random forests 18 (randomForest R package 19 ; see description in Fig 2) were built by sequentially estimating multiple classification trees (between 500 and 1,500; selected based on the stability of the out-of-bag [OOB] error; see Fig 2) using bootstrapped training cohort samples (n 5 225) with a random subset of predictors for each node. The trees in the "forest" are averaged together, providing more reliable predictions than are possible using a single classification tree. Biomarkers and biomarker ratios were natural log-transformed prior to classifier construction. Variable importance measures (average decrease in 
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accuracy from permuting each covariate across all trees) 20, 21 evaluated the contribution of individual biomarkers to the classifier. The R code for constructing these classifiers is provided as Supplementary File 1.
Results
SOMAscan Assay on CSF Samples
Using SOMAscan, we analyzed CSF samples in blinded fashion in 2 independent cohorts of subjects (Table) : (1) Table 2 ) was 11.9% and 12.9%, respectively. To determine the effect of immunomodulatory DMT on SOMAmers, we analyzed 10 longitudinal CSF samples from 5 OIND patients collected before and after therapy with high-dose methylprednisolone. The resulting average relative percentage change of 52.1% exceeded the highest technical and biological relative percentage change. Therefore, we concluded that the SOMAscan reliably measures CSF biomarkers and can detect an effect of DMT in subjects over time.
Development of Diagnostic Tests for MS
Considering the complex biological mechanisms underlying MS, a single biomarker cannot reliably differentiate MS from all other CNS diseases. Machine learning strategies, 18 such as random forests, 19 combine multiple biomarkers using a statistical algorithm that enhances sensitivity and specificity, 22 resulting in clinically useful classifiers (see Fig 2 for explanation of the random forests algorithm). We employed random forests trained using the modeling (n 5 225) cohort to develop 3 classifiers: (1) one that differentiates MS from all other diagnostic groups, (2) one that differentiates RRMS from progressive MS (ie, PPMS 1 SPMS), and (3) one that differentiates PPMS from SPMS. Because the validity of the classifier must be tested in an independent cohort not used for the model construction, 23 we assessed the performance of the diagnostic tests in the independent (n 5 85) cohort by predicting AUROCs and their CIs (Fig 3) . Classifiers that used all 1,128 SOMAmers achieved validated AUROC 5 0.91 (95% CI 5 0.84-0.97) for the MS versus non-MS test, AUROC 5 0.73 (95% CI 5 0.57-0.90) for the RRMS versus progressive MS test, and AUROC 5 0.64 (95% CI 5 0.44-0.84) for the SPMS versus PPMS test (see Fig 3) .
We expected that not all 1,128 proteins measured by SOMAscan will be detectable in the CSF. We filtered out noise stemming from the poorly detectable biomarkers by restricting the number of SOMAmers to the 500 with the highest SNR (see Subjects and Methods for details). We reasoned that the most useful biomarkers will vary greatly among subjects from different diagnostic categories, whereas they will have stable physiological levels (ie, they will have low variance in biological replicates of HDs) and can be measured with high precision (ie, low variance in technical replicates). This reduced set of 500 biomarkers (Supplementary Table 3 . The x-axes correspond to the patient/sample that the measurements were produced from. The upper panels show technical replicates (n 5 88), and the lower panels show biological replicates (n 5 24). The left panels show the raw measurements (natural-log scale relative fluorescent units [RFUs]) for SOMAmer SL004672 for each sample on the y-axes. The right panels show the identical raw observations with the random intercept effect subtracted to account for subject-to-subject variation. These residuals (after subtracting means of technical or biological replicates) were used to estimate the technical and biological variance, respectively. The horizontal black lines are the estimated mean from the technical (top graphs) and biological (bottom graphs) variance models. (B) Differences in biomarker measurements in identical samples analyzed repeatedly (technical replicates, n 5 88, left), in longitudinal healthy donor samples measured at different time points (biological replicates, n 5 24, middle), and in patient samples before and after application of immunomodulatory therapy (biological changes, n 5 10, right) were quantified in 2 ways: (1) an average of Spearman rho values calculated across 500 high-signaling SOMAmers with high SNR, and (2) an average of variabilities (a median of relative percentage changes calculated as absolute difference of RFUs for each of the 500 high-signaling SOMAmers between 2 replicates divided by the average of the 2 RFUs) for all pairs of replicates in each respective category. Examples of the strongest and the weakest correlations between 2 samples in each category are visualized on 500 high-signaling SOMAmers. The axes show log10 scales of RFUs of SOMAmers. CSF 5 cerebrospinal fluid; SD 5 standard deviation.
MS marginally improved (AUROC 5 0.92, 95% CI 5 0.86-0.98), and remained unchanged for SPMS versus PPMS test (see Fig 3) .
Although biomarkers are secreted by diverse cells under physiological or pathological states, many biomarkers are biologically related; for example, they physically interact or belong to the same network. However, random forests consider biomarkers only sequentially within any given tree. For related biomarkers, such as receptor-ligand pairs, the pathogenic process may depend more on their stoichiometry than on their respective concentrations. Therefore, we hypothesized that considering FIGURE 2: Highly simplified artificial example explaining the principles of random forests. (A) A decision tree differentiates groups of observations (elements) using selected features. For example, to differentiate relapsing-remitting multiple sclerosis (RRMS) from progressive multiple sclerosis (MS), useful features may be magnetic resonance imaging (MRI) contrast-enhancing lesions (CELs) and T2 lesions, IgG index, and disability. (B) Assembling features into a decision tree provides better results than classifying based on any single feature. A decision tree algorithm selects from available features one that best differentiates diagnostic categories and computes its optimal threshold (ie, the value on which to split the elements). The algorithm then finds the next best feature to split the categories, and this process repeats itself until meeting termination criterion, for example, when a certain number of splits has occurred. The number of splits corresponds to the depth of a tree. A random forest algorithm mitigates the problem of unreliable predictions by using a collection of decision trees, each generated slightly differently, using a random subset of features and elements. First, the algorithm restricts the number of features from which each new tree is constructed; if testing p features, the algorithm randomly selects ͱp features available for every split in a tree. Second, each tree is constructed from a random sample of patients (with replacement) of the same size as the original training cohort (bootstrapping). The observations withheld from each tree due to bootstrapping are used to calculate out-ofbag (OOB) misclassification error. In our example (C), only ͱ4 5 2 features are used for each split in the decision trees of depth 2, with each of the decision trees generated from a bootstrapped subset of the training dataset. (C) Possible partitions for CELs-T2 lesions (upper) and CELs-disability (lower) combinations of features; (D) corresponding examples of decision trees, with a total of 4 trees in the forest. The final prediction is derived as an average prediction from all randomly generated trees. For example, if 1 tree classified a patient as progressive MS but the other 3 trees classified the patient as RRMS, the subject will be classified as RRMS with 75% probability. Because of the high variability in individual trees, the algorithm is typically run for many trees until the OOB predictions stabilize. Therefore, it cannot be described by a mathematical equation or a single decision tree. (E) The randomness assures that the algorithm searches the entire p-dimensional partition space (only 3 dimensions shown, but the search space is 4-dimensional) for the best features, and by averaging the partitioning thresholds in the training cohort, the classifier also effectively derives optimal global thresholds. (F) By calculating the average OOB error when a feature is omitted from the construction of a tree, we can generate a global "variable importance" metric that reflects decrease in accuracy of the random forest classifier in the absence of the specific feature. related biomarkers simultaneously, for example as ratios, will add discriminatory value. Mathematically, this corresponds to broadening the biomarker-based random forests from partitioning the predictor space based on absolute concentrations of individual markers (represented by blue dotted perpendicular lines in Fig 2C) to considering predictors built from the relative proportion of biomarkers (represented by diagonal orange line in Fig 2C) . Consequently, we used the 500 high-SNR SOMAmers to generate 124,750 biomarker ratios. To build random forests only from ratios with the highest clinical utility, we combined AUROC with SNR values in the modeling (n 5 225) cohort, selecting logical cutoffs described in Subjects and Methods that allowed for enough diversity to capture the biological processes while limiting the dimension of the search space. This led to 5,401 retained ratios for MS versus non-MS, 3,626 retained ratios for progressive versus relapsing MS, and 1,504 retained ratios for SPMS versus PPMS. Using these sets of ratios strongly enhanced the performance of random forest models distinguishing MS from non-MS and RRMS from progressive MS (validated AUROC 5 0.95, 95% CI 5 0.91-0.99 and AUROC 5 0.88, 95% CI 5 0.76-1.00, respectively). However, the performance of SPMS versus PPMS diagnostic test remained low (AUROC 5 0.45, 95% CI 5 0.24-0.67).
A clinical test has to fulfill technical requirements of reproducible measurement across different laboratories, often achieved by using standard curves; this makes measuring several hundreds of proteins prohibitive. Therefore, we sought to identify the smallest number of biomarkers that can be assembled into the random forest classifiers without a significant loss of accuracy. To achieve this, we examined the OOB AUROC estimates from random forests generated from the modeling (n 5 225) cohort by sequentially adding ratios with the highest variable importance (see Fig 2D) . The point of inflection where the OOB AUROC appeared to stabilize was selected to achieve models with high predictive ability at a lower complexity (see Fig 3) . Interestingly, the reduction of the number of ratios further improved the performance of the classifiers in the validation cohort; the 22 most important ratios in the MS versus non-MS classifier led to validated AUROC 5 0.98 (95% CI 5 0.94-1.00), and the 21 most important ratios distinguished RRMS from progressive MS with AUROC 5 0.91 (95% CI 5 0.80-1.00; see Fig 3) . The 33 most important ratios distinguishing SPMS from PPMS led to a classifier with performance comparable to random guessing (AUROC 5 0.58, 95% CI 5 0.37-0.79), and therefore this model was abandoned from further analyses. In all 3 classifiers, variable importance measures were dominated by ratios in models that also included single SOMAmers (data not shown), validating our mathematical and biological foundation of the ratiobased hypothesis.
The clinical properties of the validated models are summarized in Figure 4 . When using 50% cutoff to convert continuous probabilities into dichotomous classifiers, the MS molecular diagnostic test shows 87.2% sensitivity (95% CI 5 77.7-96.8%) and 94.7% specificity (95% CI 5 87.6-100.0%) with a diagnostic odds ratio of 123.0. The progressive MS classifier differentiates RRMS from progressive MS with 93.5% sensitivity (95% CI 5 84.9-100.0%) and 81.3% specificity (95% CI 5 62.1-100.0%), reaching a diagnostic odds ratio of 62.8.
Deconvolution of Biomarkers' Cell of Origin
To investigate whether statistical learning preferentially selected biomarkers with restricted cellular origin into clinically useful tests, we used in vitro modeling on human primary immune and CNS cells (see Subjects and Methods), complemented with data from the public domain, such as the RNA sequencing database of human CNS cells 24, 25 and the Human Protein Atlas, 26 to assess cellular origin of the biomarkers in the optimized random forest classifiers (Figs 5 and 6 ). 
Biological Interpretation of MS versus non-MS Diagnostic Test
The 22 most important ratios of the MS diagnostic test were dominated by immune cell-specific biomarkers (see Fig 5) . Twenty-one of these contain plasma cell-specific biomarkers TNFRSF17 (BCMA) or IGG. The main insight from the MS diagnostic classifier is that in MS, activation of humoral immunity represented by plasma cells and plasmablasts is out of proportion to activation of all other cellular components of innate or adaptive immunity. Combining cellular origin and known biological functions, the biomarkers constituting the MS diagnostic test can be divided into 9 subgroups, where plasma cell activation/levels is compared to overall intrathecal inflammation (group 1a; PDCD1LG2, SLAMF6, CD48, CSF3, CXCL13, TNFRSF4) and amount of activation of myeloid lineage (groups 1b and 1c; PLA2G7, CCL7, TLR4:LY96 complex, PRTN3). MS patients also show higher plasma cell activation/levels in comparison to vascular injury and/or ongoing CNS stress (groups 1d, 2a, and 2c; FLT4, CDKN1B, TNFRSF6B, DSG2, CRK, PGK1, MAPK14, F9, DCTPP1). A ratio of IgG and IgM (group 2b) points to differences in immunoglobulin subtypes between MS and non-MS subjects. Higher plasma cell immunoglobulin secretion in comparison to levels of CNS injury and higher plasma cell activation in comparison to astrocyte activation (group 2d; TNC) was also observed in MS. Lastly, MS subjects have increased epithelial stress compared to activation of neutrophils (group 3; MMP7, PRTN3).
Biological Interpretation of Progressive MS versus RRMS Diagnostic Test
The 21 top ratios distinguish RRMS from progressive MS (see Fig 6) . Seven were ratios of EDA2R or EDAR with markers released predominantly by CNS cells, especially neurons and oligodendrocytes: STX1A, EPHA5, JAM3, NTRK3, RGMA, BOC, and UNC5 (group 1a); all of these ratios demonstrate relative loss of CNS-specific markers in progressive MS. Moreover, 3 ratios show proportional loss of neuronal and oligodendroglial markers in relation to ICOSLG, expressed on activated antigen-presenting cells, in progressive MS (group 1b; EPHA5, JAM3, TYRO3). Similarly, the ratio INHBA/ JAM3 measures relative loss of an oligodendroglial marker in comparison to a marker secreted predominantly by myeloid cells during wound healing and tissue remodeling (group 1c). Progressive MS patients also show increased epithelial stress in comparison to overall intrathecal inflammation (group 1d; SELL, EDAR).
Another group of biomarker ratios points out enhanced alternative pathways of complement activation in comparison to overall intrathecal inflammation (groups 2a and 2b; CFD, GZMA, SELL, SERPING1, IL22). Finally, a group of ratios relates to dysregulation of LTA-LTB and IL22 pathways, which play an important role in the formation of tertiary lymphoid follicles in progressive MS (groups 2c, 2d, 2e, and 3; LILRB2, SELL, LTA-LTB, IL10, PRTN3, ETHE1, GP6, CLEC1B) and also in platelet aggregation (group 3).
Discussion
Exploring recent advances in proteomics, we asked whether CSF biomarkers can reliably measure intrathecal processes and thus facilitate diagnosis, drug development, and clinical management of patients with complex CNS diseases. We hypothesized and confirmed that intraindividually stable CSF biomarkers with restricted cellular origin are over-represented in clinically useful classifiers. Collected data provide proof-of-principle evidence that molecular diagnosis of polygenic CNS diseases is feasible with current technologies. In contrast to internal medicine disciplines that utilize molecular biomarkers, 27 contemporary diagnostic process and therapeutic decisions for polygenic neurological diseases are based on clinical findings and structural imaging, both of which lack molecular specificity. This may contribute to high misclassification rate in neurodegenerative diseases against pathology. 1, 2 Finding that 1 of the first 3 "MS" subjects who succumbed to natalizumab-induced progressive multifocal leukoencephalopathy demonstrated no pathological evidence of MS 28 suggests that a >20% misdiagnosis rate may also be applicable to MS, despite advances provided by imaging. We observed approximately 10% discrepancy between clinical-and biomarker-based MS diagnosis ( Fig  7A) ; the absence of pathological evidence prevents determining which classification is correct. The majority of SOMAscan-misclassified "MS" patients lacked defining biological features of MS: intrathecal activation of plasma cells and adaptive immunity, validated by alternative assays (see Fig 7B) . Therefore, patients misclassified by molecular classifiers either exhibited a noninflammatory form of MS, observed by pathologists at frequencies analogous to our MS misclassification rate, 29 or had alternative conditions. Regardless of what we call such ailments, these patients lack targets of immunomodulatory DMTs and are unlikely to reap their benefit. Thus, providing therapeutically relevant information represents the first advantage of molecular diagnosis. The second advantage is reporting diagnostic probabilities as a continuous variable that captures the strength of biological evidence, in comparison to a dichotomous clinical diagnosis. Indeterminate results close to 50% probability (which represented 88% of subjects with discrepant clinical and molecular diagnosis; see Fig 7A) should be repeated, ideally after cessation of the acute process that prompted diagnostic testing. Diagnostic specificity is of high clinical importance, because false-positive results expose subjects to potential harms of unnecessary therapies. Because the MS diagnostic classifier is antigen-nonspecific, dysregulated immunity targeting non-MS antigens may be misclassified as MS if it elicits qualitatively similar intrathecal inflammation. We observed that 2 OIND patients (1 with CTLA-4 haploinsufficiency and another with chronic aseptic meningitis) were misclassified as MS. It is plausible that analogously to mutations shared among different cancers, conditions with pathogenic mechanisms similar to MS may respond to MS treatments. This is the third advantage of molecular taxonomy, as it could promote CNS therapeutics from disease-specific monotherapies to process-specific therapies, where treatments are shared among pathophysiologically related conditions and rationally assembled into patient-specific polypharmacy regimens.
Our study has following limitations. SOMAscan represents a selection of proteins that are not specifically targeted to the CNS. This drawback, however, also proves that molecular signatures of distinct diseases are sufficiently robust that sampling 1% of the relevant proteome can reliably differentiate among them. Our observation that unbiased statistical learning selected virtually all available SOMAmers with restricted CNS cellular origin suggests that deliberate broadening of the sampled proteome to more CNS-relevant biomarkers has a potential to improve classifications, and expand understanding of disease mechanisms. Also, SOMAscan is a discovery platform, routinely optimized and expanded, and therefore lacking standards of clinical applications. We dealt with this problem by embedding many technical replicates that allowed normalization between different assay runs. However, even after normalizing and focusing on biomarkers with high SNR, the interassay variability (measured by technical replicates) decreased the performance of the classifiers. Furthermore, during A group average is shown as a thick yellow line for PPMS, thick red line for RRMS, thick orange line for SPMS, thick purple line for HD, thick green line for NIND, and thick blue line for OIND. The y-axis shows SOMAmer natural log ratios scaled to 0-1 range. SOMAmer ratios were grouped based on the cellular origin and known functions of the individual components into 9 groups. Different cell types are shown above the PCP to highlight the cell origin of individual SOMAmers. MS patients show higher plasma cell/plasmablast activation/levels compared to overall intrathecal inflammation (group 1a), myeloid lineage (groups 1b and 1c), epithelial damage (group 1d), central nervous system (CNS) destruction and epithelial injury (group 2a), differences in immunoglobulin subtypes (group 2b), CNS and endothelial damage (group 2c), astrocyte activation (group 2d), and higher epithelial injury compared to neutrophil activation (group 3). *Ratios in the classifier are inverted. BBB 5 blood-brain barrier; IT 5 intrathecal.
the submission and review of this article, Somalogic updated SOMAscan from an assay that quantifies 1,128 proteins to an assay that uses different buffers and dilutions, and quantifies 1,300 proteins. We subsequently used the original validation cohort to test whether random forests constructed from the selected set of , primary progressive MS, secondary progressive MS). The red line represents an arbitrary cutoff at 50%. The pink background marks an area between 30% and 70% where the certainty of the molecular classification is weak (contains 22.4% of the validation cohort's subjects). The orange background highlights 70.0% of the validation cohort's MS subjects with highly probable MS molecular diagnosis (>70%), and the blue background labels 86.8% of the validation cohort's non-MS subjects with high probability of non-MS molecular diagnosis (<30%). The gray bars represent a frequency distribution bar chart with the bin size of 5%. (B) Misdiagnosed subjects (pink circles) were evaluated for non-SOMAlogic biomarkers of inflammation-IgG index, BCMA, sCD27, and CHI3L1-using alternative assays (for details on methodology, see Komori et al 34 ). The group medians are shown for MS subjects as an orange line and for non-MS subjects as a blue line. The 7 MS subjects who were classified as non-MS by the molecular diagnostic test showed a noninflammatory type of disease, whereas the 2 non-MS (OIND) subjects who were categorized as MS according to the SOMAlogic MS molecular classifier showed significant levels of inflammatory markers, overlapping with MS. (C) Comparison of IgG index data (left) and molecular MS diagnostic probability (right) in the combined modeling and validation cohort shows distributions of non-MS (blue circles) and MS subjects (orange circles). The black dotted lines on the left show lower and upper limit of normal IgG Index and on the right the 50% cut off for MS molecular diagnostic test. (D) Separation of RRMS (green circles) and progressive MS (PMS; purple circles) subjects into 2 age categories (<45 years, left side and >45 years, right side) shows that age does not affect performance of the progressive MS classifier. The black dotted line shows the 50% cut off for progressive MS diagnostic test.
biomarker ratios depicted in Figures 5 and 6 can still reliably differentiate MS from other diseases and RRMS from progressive MS using the new version of SOMAscan. We observed OOB AUROC of 0.89 (95% CI 5 0.82-0.97) for MS versus non-MS classifier and OOB AUROC of 0.84 (95% CI 5 0.66-1.00) for RRMS versus progressive MS classifier. This shows that our results are not assay-dependent, but reflect true biological processes. Nevertheless, biomarker-based precision neurology cannot be achieved without the biotech industry, which needs to develop fully quantitative, CSF-targeted assays that conform to technical requirements of clinical tests. To facilitate this, we considered "assay economy," as an optimum between assay cost (dependent on the number of proteins that need absolute and relative quantification) and accuracy. Biomarker ratios simplify assay commercialization, by limiting the need to run standard curves for every analyte and providing internal normalization that avoids false-positive results caused by, for example, high protein levels. However, absolute quantification of at least the dominant biomarker partners, such as BCMA and EDA2R, will likely be necessary for quality assurance for clinical applications.
The creative use of SNR screened out biomarkers of low clinical value; this improved the efficacy of the random forest algorithm, which searched for optimal biomarkers in the lower dimensional search space. Although such use of external data and domain-expert knowledge is encouraged in statistical learning, as it typically improves performance (as it did in our case), we acknowledge that this methodology leads to some arbitrariness in the selection of markers, and thus it may not work in other settings or for other cohorts. To assure adequate representation of all MS subtypes and both inflammatory and noninflammatory MS mimics in the classifier construction, we designed this study to have approximately equal representation from all patient groups. This may not be representative of the rates in the real population of patients, where, for example, RRMS/SPMS patients are much more frequently encountered than PPMS subjects. Because SNR is dependent on the composition of the training cohort, we acknowledge that different compositions of the training cohort may lead to selection of different biomarkers, potentially better or worse for separating certain disease states. This behavior is inherent to any statistical learning process and, therefore, sampling and population structure must be considered carefully in the study design. We view our population selection as appropriate for the stated goals, because in addition to HDs, controls included subjects with varied inflammatory and noninflammatory CNS diseases, who presented for the diagnostic workup of MS or related neuroimmunological diseases and who must be differentiated from all 3 MS subtypes.
Supporting the notion that CSF biomarkers can expand understanding of CNS diseases, the following knowledge was gained from the current study. The essential difference between MS and its mimics is selective expansion/activation of B-cell/plasma cell lineages, out of proportion to the activation of other immune cells and to the resultant injury/stress of CNS-resident cells. An ancillary pathway that helps to diagnose MS is linked to a marker of tissue remodeling and repair, MMP7. These features are shared by all MS subtypes, indicating that PPMS is not a pathophysiologically distinct "non-inflammatory" entity, 30 but rather an equivalent disease stage to SPMS. This conclusion is supported by the observed inability to validate a molecular classifier that differentiates PPMS from SPMS with accuracy higher than random guessing and by therapeutic response of PPMS to immunomodulation by ocrelizumab. 31 The dominance of plasma cell biomarkers in the molecular classifier poses a question of its value against current CSF tests such as IgG index and oligoclonal bands (OCBs). We have included IgG index and MS classifier prediction rates to Figure 7C to demonstrate the superiority of the classifier. Similar data were obtained for OCBs; in the cohort of patients with available OCB data, the sensitivity of the OCB test (93.9%, 95% CI 5 90.3-97.6%) was comparable to the sensitivity of molecular classifier (96.4%, 95% CI 5 93.5-99.2%), and the specificity of the OCB test (80.0%, 95% CI 5 72.8-87.2%) was highly outperformed by the specificity of the molecular classifier (98.3%, 95% CI 5 96.0-100.0%).
Statistical learning also enhanced our understanding of progressive MS by demonstrating that PPMS and SPMS are biologically indistinguishable. These data argue for merging PPMS and SPMS cohorts in future drug development and clinical considerations. Features that differentiate progressive MS from RRMS are greater CNS tissue destruction, including more widespread endothelial/ epithelial cell stress, and reactive gliosis with increased permeability of CNS barriers and greater activation of innate immunity. In addition to proportional loss of oligodendroglial and neuronal biomarkers that likely reflect injury or loss of their cells of origin, there are also immunological differences between RRMS and progressive MS. These relate to innate immunity (complement, myeloid lineage, and antigen presentation), and to pathways involved in the formation of tertiary lymphoid follicles, such as lymphotoxin complex and IL22. This is consistent with the pathological evidence of tertiary lymphoid follicles in progressive MS 32 and with a recent report that the level of compartmentalization of immune responses to the CNS can differentiate RRMS from 2 progressive MS subtypes. 6 Finally, it is intriguing that 4 of 21 ratios that differentiate progressive MS from RRMS (ie, containing SERPING1 and CFD, which is essential in alternative complement activation by cleaving C3) are linked to "neurotoxic reactive astrocytes," recently shown to mediate neuronal death in MS and other neurodegenerative diseases. 33 One may ask to what degree the identified MS progression-specific processes reflect aging. Reanalyzing probabilities of progressive MS in patients younger and older than 45 years demonstrated that the molecular classifier correctly differentiates RRMS from progressive MS irrespective of age (see Fig 7D) . Thus, the biological interpretation of MS classifiers offers the following unifying hypothesis for future longitudinal studies: although aberrant activation of B-/plasma cell lineage is essential for development of MS, the complex response of CNS tissue, exemplified by microglial activation, toxic astrogliosis, and endothelial/epithelial stress, determines the extent and irreversibility of demyelination and neuronal death, which underlie progressive accumulation of disability in MS.
Although longitudinal data represented only a small part of the current study, they were instrumental for selecting high SNR biomarkers, which improved the accuracy of the molecular classifiers. They also demonstrated the ability of CSF biomarkers to measure broad biological effects of applied therapies in the intrathecal compartment. Expanding CSF biomarker studies to longitudinal cohorts could identify molecular signatures that forecast therapeutic efficacy, as well as biological synergisms among different treatments. Longitudinal cohorts are also required to determine the extent and stability of pathogenic heterogeneity. 29 Implementation of CSF biomarkers in phase I/II trials can guide dose and patient selection, and eliminate unpromising agents without accruing excessive costs and sequestering large numbers of available patients. 34 Such biomarker-supported trials thus offer the promise to propel CSF biomarker-based precision medicine into neurology practice. Although the presented results make these prospects realistic, they cannot be achieved without broader, visionary investment of efforts and resources to exploit the full potential of CSF biomarkers in neurology.
